Breaks Categories: Stock Spotlights

ThursdayFeb 02, 2023 1:31 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Elevate Drug Delivery Across Blood-Brain Barrier by ~1,900%

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, has developed its patented DehydraTECH(TM) technology, which is designed for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. “DehydraTECH increases effectiveness and improves how these ingredients enter the bloodstream. Benefits of DehydraTECH include: improved speed of onset, with effects felt in minutes; increased bioavailability, with more of the drug delivered into the bloodstream; increased brain absorption, with testing suggesting up to 10x improvement; and improved drug potency, with more of the ingested product made available in the bloodstream requiring lower dosages,” a recent article reads. “Animal studies…

Continue Reading

WednesdayFeb 01, 2023 1:33 pm

CannabisNewsBreaks – REZYFi Inc. Ideally Positioned as USDA Pushes Hemp Conversation Forward

REZYFi, a growth mortgage origination and specialized financing company that targets licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies and companies and individual homeowners, is set to benefit from the growing support for the cannabis industry. “The United States Department of Agriculture (‘USDA’) is set to include hemp data in its 2022 Census of Agriculture. It is noted that with this inclusion, the organization is pushing the conversation around hemp and marijuana forward. It also signals the eventual integration and support of the overall cannabis industry. With this support, various companies within the sector…

Continue Reading

WednesdayJan 25, 2023 12:56 pm

CannabisNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Advances Novel Drug Candidate in Treating Alzheimer’s Symptoms

India Globalization Capital (NYSE American: IGC), in a historic first, has begun phase 2 clinical trials evaluating its flagship drug candidate, IGC-AD1, for the treatment of agitation in dementia from Alzheimer’s disease. “Company officials noted that, to their knowledge, this is the first natural low-dose THC-based compound to enter human trials for the treatment of symptoms such as agitation in dementia from Alzheimer’s disease. Currently there is no FDA-approved medication to treat agitation in Alzheimer’s,” reads a recent article. The piece quotes IGC CEO Ram Mukunda, who states, “We believe IGC-AD1 has the potential to revolutionize the treatment of the…

Continue Reading

TuesdayJan 24, 2023 11:14 am

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Working Toward Global Leadership in CBD Space

Flora (NASDAQ: FLGC) has transitioned from the development stage to a full-scale international distributor with operations in over 12 countries worldwide, achieved under Luis Merchan’s tenure as CEO. “Merchan has also spearheaded several mergers and acquisitions, most notably JustCBD and Vessel Brand, which have since set the company up for rapid growth. Flora also secured $34.5 million in financing and signed deals with key retail distributors such as Tropi, a Colombia-based distributor, Walmart and Macy’s. The company also completed its first import of CBD-containing food and beverage products into the United States from Colombia under its Mambe brand. It has…

Continue Reading

FridayJan 13, 2023 3:45 pm

CannabisNewsBreaks – REZYFi Inc. Positioning to Operate Competitively in Challenging Lending Markets

REZYFi, a specialized financing company and a growing mortgage lender, is working to help businesses navigate the challenging landscape of loan origination, particularly as it applies to the traditionally underserved cannabis industry and property owners who lease to such companies. “REZYFi is anticipating the launch of its high-margin cannabis division in the coming weeks to focus on such challenging lending markets. The company is developing a proprietary technology that will help it operate competitively by maintaining efficient turnaround time while also being economical with staffing levels,” a recent article reads. “Through its subsidiaries, REZYFi Lending and ResMac Inc., the company…

Continue Reading

ThursdayJan 12, 2023 2:32 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves Closer Toward Broad Applications of Patented DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX) in 2022 achieved crucial milestones centered around its patented DehydraTECH(TM) drug delivery technology. “For Lexaria, the end goal does not only lie in uncovering DehydraTECH’s ability to improve the bioavailability of various APIs. Instead, the company is keen on establishing whether DehydraTECH can be applied broadly within the pharmaceutical industry. And calendar 2022 has brought Lexaria closer to realizing this goal, with the company initiating a slew of research programs, many of which it has already completed. Moreover, its intellectual property (‘IP’) portfolio received additional patent protection in different jurisdictions around the world. Lexaria also…

Continue Reading

MondayJan 09, 2023 1:13 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Leveraging Colombia, US Facilities to Distinguish Itself Within Highly Competitive Space

Flora Growth Corp. (NASDAQ: FLGC), a cannabis cultivator and global distributor, is a rapidly growing house of brands building customer bases and distribution channels across international lines as it aims to distinguish itself within a highly competitive arena. “Much of Flora Growth’s strength lies in its licensed cultivation, extraction and isolation facility located in northern Colombia’s fertile climate, where an experienced labor force is helping the nation emerge from decades of drug war illicit trade into a recognized and regulated market,” a recent article reads. “From its 247 acres of growing fields, the company’s harvests move into a production pipeline…

Continue Reading

MondayDec 19, 2022 12:56 pm

CannabisNewsBreaks – REZYFi Inc. Tailoring Financing Packages to Meet Unique Needs of Cannabis Businesses

REZYFi seeks to fill an existing funding gap, where cannabis business operators face perpetual difficulty accessing capital in the form of loans and mortgages from Federal Deposit Insurance Corporation (“FDIC”)-insured banks and financial institutions. “REZYFi regards itself as a real estate-oriented mortgage company servicing the needs of both traditional and non-traditional consumers and businesses, but with a primary focus on the cannabis sector. The company mainly offers mortgage origination and specialized financing to licensed and permitted cannabis companies and owners of real estate who lease to cannabis companies,” a recent article reads. “Leveraging its team’s significant experience in a wide…

Continue Reading

FridayDec 16, 2022 3:21 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Expected to Yield Notable Results in Diabetes Study

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global leader in enhancing the speed and efficiency of orally delivered fat-soluble active molecules and drugs. “Lexaria [recently] announced that the study program DIAB-A22-1 [had begun] on schedule, making it the company’s first-ever study to investigate whether its DehydraTECH-processed cannabidiol (‘CBD’) may potentially have therapeutic utility against diabetes,” a recent article reads. “Lexaria is optimistic that its DehydraTECH-CBD will yield notable results from this study, especially having met primary safety and efficacy objectives from its HYPER-H21-4 clinical study. There is a strong connection between heart disease, hypertension and diabetes, with hypertension proving to…

Continue Reading

ThursdayDec 08, 2022 1:50 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Latest DehydraTECH-CBD Study May Be 1st to Evidence Sustained Drop in Blood Pressure

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global leader in enhancing the speed and efficiency of orally delivered fat-soluble active molecules and drugs, has, since inception, been committed to addressing severe unmet patient needs. Hypertension has been one of its main focus areas. “Lexaria continues to move forward, most recently with the success in its latest human clinical study, HYPER-H21-4. The study may be the first to evidence a sustained drop in blood pressure in normally active patients following multiple weeks of oral cannabidiol (‘CBD’) therapy using the company’s patented DehydraTECH(TM) technology,” reads a recent article. “Since Lexaria began developing DehydraTECH…

Continue Reading